Cycle Pharmaceuticals Acquires Applied Therapeutics in $0.088 Per Share Deal to Advance Rare Disease Pipeline
Key Insights
Cycle Group Holdings Limited (search) announced a definitive agreement to acquire Applied Therapeutics for $0.088 per share plus contingent value rights worth up to $0.40 per share.
The acquisition focuses on advancing govorestat, Applied's lead CNS-penetrant aldose reductase (search) inhibitor targeting rare metabolic diseases including Classic Galactosemia (search) and CMT-SORD (search).
Applied Therapeutics received an $8.5 million promissory note from Cycle to fund operations, as the company would otherwise be unable to continue activities for more than a limited number of days.
Cycle Group Holdings Limited (search) announced a definitive agreement to acquire Applied Therapeutics, Inc. (Nasdaq: APLT) for $0.088 per share in cash plus contingent value rights that could provide shareholders with up to $0.40 per share in additional payments based on regulatory and commercial milestones.
The acquisition centers on Applied's lead drug candidate govorestat, a novel central nervous system penetrant aldose reductase (search) inhibitor designed to treat rare metabolic diseases including Classic Galactosemia (search), Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (search) (CMT-SORD (search)), and phosphomannomutase 2 congenital disorder of glycosylation (search) (PMM2-CDG (search)).
Strategic Rationale and Financial Structure
"We are confident that Cycle has the resources and capabilities to move govorestat forward towards the ultimate goal of bringing a life-changing treatment to the patients suffering from Classic Galactosemia (search), CMT-SORD (search) and PMM2-CDG (search), who have always been at the center of everything we do at Applied," said Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer of Applied Therapeutics.
The contingent value rights provide structured milestone payments tied to regulatory achievements and commercial success. Shareholders will receive up to $0.10 per CVR upon FDA approval for galactosemia indications, up to $0.10 per CVR for CMT-SORD (search) indication approval, and up to $0.20 per CVR when worldwide net sales reach $200 million in any four-quarter period. All milestone payments must occur within eight years of closing for regulatory approvals and ten years for sales milestones.
Critical Financial Support
Applied Therapeutics also received a promissory note enabling loans of up to $8.5 million from Cycle to fund working capital needs under an approved budget. Without this funding or alternative sources, Applied would be unable to continue operations for more than a limited number of days and would anticipate winding down operations.
The transaction was unanimously approved by Applied's Board of Directors following an extensive evaluation of strategic alternatives that included numerous discussions with potential counterparties. The Board determined that the merger agreement with Cycle represented the path that best advanced the interests of Applied and its stockholders.
Company Profiles and Market Focus
Cycle Pharmaceuticals, founded in 2012, focuses exclusively on delivering drug treatments to the underserved rare disease community. The Cambridge, UK-based company with Detroit offices concentrates on rare genetic conditions in metabolic, immunology, urology, and oncology areas, with additional focus on multiple sclerosis (search) in neurology.
Applied Therapeutics operates as a clinical-stage biopharmaceutical company committed to developing novel drug candidates against validated molecular targets in rare diseases. The company's lead asset govorestat represents a novel approach to treating CNS rare metabolic diseases through aldose reductase (search) inhibition.
Transaction Timeline and Conditions
The merger agreement does not include a financing condition, and the transaction is expected to close in the first quarter of 2026, subject to satisfaction of customary closing conditions including the tender of a majority of outstanding Applied common stock. Cycle will commence a tender offer to acquire all outstanding shares, with any untendered shares acquired through a second-step merger for identical consideration.
For the transaction, Goodwin Procter LLP serves as legal counsel for Cycle, while Applied engaged Aquilo Partners, L.P. for a fairness opinion and Ropes & Gray LLP as legal counsel.